CSF biomarkers for Alzheimer's disease: use in early diagnosis and evaluation of drug treatment (Q36252166)

13 August 2017

1 reference

title

CSF biomarkers for Alzheimer's disease: use in early diagnosis and evaluation of drug treatment (English)

1 reference

13 August 2017

0 references

0 references

1

Kaj Blennow

1 reference

13 August 2017

publication date

1 September 2005

1 reference

Expert Review of Molecular Diagnostics: new diagnostic technologies are set to revolutionise healthcare

13 August 2017

published in

1 reference

13 August 2017

volume

5

1 reference

13 August 2017

issue

5

1 reference

13 August 2017

page(s)

661-672

1 reference

Mild cognitive impairment: clinical characterization and outcome

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Amyloid plaque core protein in Alzheimer disease and Down syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

APH-1 is a multipass membrane protein essential for the Notch signaling pathway in Caenorhabditis elegans embryos

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Amyloid beta-peptide is produced by cultured cells during normal metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Decreased levels of soluble amyloid beta-protein precursor in cerebrospinal fluid of live Alzheimer disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Low cerebrospinal-fluid concentrations of soluble amyloid beta-protein precursor in hereditary Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Soluble amyloid beta-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Age-dependent change in the levels of Abeta40 and Abeta42 in cerebrospinal fluid from control subjects, and a decrease in the ratio of Abeta42 to Abeta40 level in cerebrospinal fluid from Alzheimer's disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Statin treatment and a disease-specific pattern of beta-amyloid peptides in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

The amyloid-beta (Abeta) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated Abeta peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients : an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

CSF markers for incipient Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

CSF tau protein and beta-amyloid (1-42) in Alzheimer's disease diagnosis: discrimination from normal ageing and other dementias in the Greek population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Both total and phosphorylated tau are increased in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Decreased Cerebrospinal Fluid Acetylcholinesterase in Patients with Subcortical Ischemic Vascular Dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Tau International Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Cerebrospinal fluid TAU protein and amyloid beta42 in mild cognitive impairment: prediction of progression to Alzheimer's disease and correlation with the neuropsychological examination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Cerebrospinal fluid markers for prediction of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Cerebrospinal fluid acetylcholinesterase activity after long-term treatment with donepezil and rivastigmina.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Invited review: Cholinesterase inhibitors for Alzheimer's disease therapy: from tacrine to future applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Lewy Body Pathology in Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Diagnostic accuracy of Alzheimer's disease: a clinicopathological study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Diagnostic accuracy of Alzheimer's disease: a neuropathological study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Quantitative measurement of changes in amyloid-beta(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Current developments in SELDI affinity technology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Reproducibility of tryptic digestion investigated by quantitative fourier transform ion cyclotron resonance mass spectrometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

Tau protein isoforms, phosphorylation and role in neurodegenerative disorders11These authors contributed equally to this work

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737159.5.5.661

21 January 2018

Identifiers

DOI

10.1586/14737159.5.5.661

1 reference

13 August 2017

1 reference